HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Abstract
Complement activation, an integral arm of innate immunity, may be the critical link to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Whereas we have previously reported elevated anaphylatoxins-complement component 3a (C3a) and complement component 5a (C5a)-in IPF, which interact with TGF-β and augment epithelial injury in vitro, their role in IPF pathogenesis remains unclear. The objective of the current study is to determine the mechanistic role of the binding of C3a/C5a to their respective receptors (C3aR and C5aR) in the progression of lung fibrosis. In normal primary human fetal lung fibroblasts, C3a and C5a induces mesenchymal activation, matrix synthesis, and the expression of their respective receptors. We investigated the role of C3aR and C5aR in lung fibrosis by using bleomycin-injured mice with fibrotic lungs, elevated local C3a and C5a, and overexpression of their receptors via pharmacologic and RNA interference interventions. Histopathologic examination revealed an arrest in disease progression and attenuated lung collagen deposition (Masson's trichrome, hydroxyproline, collagen type I α 1 chain, and collagen type I α 2 chain). Pharmacologic or RNA interference-specific interventions suppressed complement activation (C3a and C5a) and soluble terminal complement complex formation (C5b-9) locally and active TGF-β1 systemically. C3aR/C5aR antagonists suppressed local mRNA expressions of tgfb2, tgfbr1/2, ltbp1/2, serpine1, tsp1, bmp1/4, pdgfbb, igf1, but restored the proteoglycan, dcn Clinically, compared with pathologically normal human subjects, patients with IPF presented local induction of C5aR, local and systemic induction of soluble C5b-9, and amplified expression of C3aR/C5aR in lesions. The blockade of C3aR and C5aR arrested the progression of fibrosis by attenuating local complement activation and TGF-β/bone morphologic protein signaling as well as restoring decorin, which suggests a promising therapeutic strategy for patients with IPF.-Gu, H., Fisher, A. J., Mickler, E. A., Duerson, F., III, Cummings, O. W., Peters-Golden, M., Twigg, H. L., III, Woodruff, T. M., Wilkes, D. S., Vittal, R. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
AuthorsHongmei Gu, Amanda J Fisher, Elizabeth A Mickler, Frank Duerson 3rd, Oscar W Cummings, Marc Peters-Golden, Homer L Twigg 3rd, Trent M Woodruff, David S Wilkes, Ragini Vittal
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 30 Issue 6 Pg. 2336-50 (06 2016) ISSN: 1530-6860 [Electronic] United States
PMID26956419 (Publication Type: Journal Article)
Copyright© FASEB.
Chemical References
  • Antibiotics, Antineoplastic
  • COL1A1 protein, human
  • Collagen Type I, alpha 1 Chain
  • Complement Membrane Attack Complex
  • Receptor, Anaphylatoxin C5a
  • Receptors, Complement
  • Transforming Growth Factor beta
  • complement C3a receptor
  • Bleomycin
Topics
  • Aged
  • Aged, 80 and over
  • Animals
  • Antibiotics, Antineoplastic (toxicity)
  • Bleomycin (toxicity)
  • Cell Line
  • Collagen Type I, alpha 1 Chain
  • Complement Membrane Attack Complex (genetics, metabolism)
  • Down-Regulation
  • Fibroblasts (metabolism)
  • Gene Expression Regulation (physiology)
  • Humans
  • Lung Injury (chemically induced)
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Pulmonary Fibrosis (chemically induced, metabolism)
  • RNA Interference
  • Receptor, Anaphylatoxin C5a (genetics, metabolism)
  • Receptors, Complement (genetics, metabolism)
  • Signal Transduction (physiology)
  • Transforming Growth Factor beta (genetics, metabolism)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: